Catalyst Wire Dossier Catalyst Wire Dossier

APL-101

· Apollomics Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for APL-101, covering 2025-06-27 to 2026-01-20. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

See pricing